7 completed, 1 active not recruiting. 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow astegolimab: new trials by email Literature Review of astegolimab trials Research Report on astegolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects Astegolimab - Healthy Volunteers | Phase 1 | Completed | Genentech, Inc. | 78 | 2024-06-17 | 2025-01-30 |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Astegolimab - Chronic Obstructive Pulmonary Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 2000 | 2023-06-28 | 2026-08-14 |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Astegolimab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Hoffmann-La Roche | 1380 | 2022-12-29 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Astegolimab, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Genentech, Inc. | 1334 | 2021-10-05 | 2026-10-16 |
| A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia MSTT1041A, MSTT1041A-matched Placebo, UTTR1147A - COVID-19 Pneumonia | Phase 2 | Completed | Genentech, Inc. | 396 | 2020-06-02 | 2022-01-10 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis MSTT1041A, Placebo - Atopic Dermatitis | Phase 2 | Completed | Genentech, Inc. | 65 | 2019-02-06 | 2023-05-06 |
| Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) MSTT1041A, Placebo - COPD Exacerbation | Phase 2 | Completed | University of Leicester | 81 | 2018-10-11 | 2022-06-21 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma MSTT1041A, Placebo - Asthma | Phase 2 | Completed | Hoffmann-La Roche | 517 | 2016-09-20 | 2022-12-28 |
Pulmonary Disease, Chronic Obstructive (4) · Asthma (1) · Dermatitis, Atopic (1)
Genentech, Inc. (4) · Hoffmann-La Roche (3) · University of Leicester (1)
United States (7) · Germany (5) · Poland (5) · Argentina (4) · Belgium (4) · Bulgaria (4) · Canada (4) · Czechia (4) · New Zealand (4) · South Africa (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Australia (3) · Brazil (3)
Christopher Brightling, Prof (1)
PMID 42148875, PMID 42150581, PMID 33872652, PMID 35339234, PMID 36253275, PMID 36519984
2018 (2), 2016 (1)